1-20 of 122
Richard T. Maziarz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open Label Expanded Access Program

Mitchell Horwitz, Stephanie B. Tsai, Andrew R. Rezvani, Richard T Maziarz, Uri Goshen, Stuart Levy, Aurelie Schwarzbach, Roei D. Mazor, Patrick J. Stiff, Gary J. Schiller
Journal: Blood
Blood (2023) 142 (Supplement 1): 6894.
https://doi.org/10.1182/blood-2023-181167
Published: 2023
Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Uma M. Borate, Yazan F. Madanat, Cristina Tognon, Shikha Mishra, Andy Kaempf, Prapti A. Patel, Stephen E. Kurtz, Kara Johnson, Sumithira Vasu, Sharyn D. Baker, Bridget A Robinson, Tania Q Vu, Christopher A. Eide, Jessica Minnier, Yiqing Zhang, Peter Clement, Sammantha Avaylon, Thomas Jacob, Rachel Cook, Arpita Gandhi, Jessica T. Leonard, Brandon Hayes-Lattin, Laura F. Newell, Richard T Maziarz, Elie Traer, Ronan T. Swords, Jeffrey W Tyner, Brian J. Druker, Jennifer N. Saultz
Journal: Blood
Blood (2023) 142 (Supplement 1): 1515.
https://doi.org/10.1182/blood-2023-191166
Published: 2023
Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Guido Ghilardi, Staci Williamson, Raymone Pajarillo, Luca Paruzzo, Linhui Chen, Connor Grady, Abigail Doucette, Eneida R Nemecek, Giulia Gabrielli, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Rebecca Yelton, Dwivedy S. Nasta, Daniel J. Landsburg, Ositadimma Ugwuanyi, Andy Chen, Levanto Schachter, Griffin W White, Hatcher Ballard, Elizabeth Weber, Cara Curley, David L. Porter, Alfred L. Garfall, Wei-Ting Hwang, Carmen E Guerra, Richard T Maziarz, Stephen J Schuster, Marco Ruella
Journal: Blood
Blood (2023) 142 (Supplement 1): 2416.
https://doi.org/10.1182/blood-2023-187524
Published: 2023
Journal Articles

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Rakesh Awasthi, Edward Waldron, Stephan Grupp, Michael A. Pulsipher, Peter Bader, Stephen J Schuster, Richard T Maziarz, Edmund K. Waller, Ulrich Jaeger, Catherine Thieblemont, Martin Dreyling, Nathan Fowler, Harald Jakob Maier, Jennifer Willert
Journal: Blood
Blood (2023) 142 (Supplement 1): 4872.
https://doi.org/10.1182/blood-2023-181663
Published: 2023
Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Jennifer N. Saultz, Manoj Rai, Faith Burns, Daniel J Chandra, Sunil K Joshi, Curtis A. Lachowiez, Andy Kaempf, Andrew N Nemecek, Yoko Kosaka, Evan F. Lind, Stephen E. Kurtz, Nicola Long, Rachel Cook, Gabrielle Meyers, Arpita Gandhi, Jessica T. Leonard, Brandon Hayes-Lattin, Laura F. Newell, Richard T Maziarz, Elie Traer, Ronan T. Swords, Theodore P Braun, Cristina Tognon, Jeffrey W Tyner
Journal: Blood
Blood (2023) 142 (Supplement 1): 5762.
https://doi.org/10.1182/blood-2023-188311
Published: 2023
Journal Articles

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav N. Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L Phillips, Lea M Burke, Jing Lei, Rodica Morariu-Zamfir, John F. DiPersio
Journal: Blood
Blood (2023) 142 (Supplement 1): 356.
https://doi.org/10.1182/blood-2023-180205
Published: 2023
Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Journal: Blood
Blood (2023) 142 (Supplement 1): 617.
https://doi.org/10.1182/blood-2023-184862
Published: 2023
Journal Articles

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Jessica T. Leonard, Amrita Desai, Peter Ferreira-Gandolfo, Denise Lackey, Kevin Christmas, Richard T Maziarz, Eneida R Nemecek
Journal: Blood
Blood (2023) 142 (Supplement 1): 2405.
https://doi.org/10.1182/blood-2023-177864
Published: 2023
Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Curtis A. Lachowiez, Christopher A. Eide, Stephen E. Kurtz, Nicola Long, Manoj Rai, Wei Xie, Andy Kaempf, Daniel Bottomly, Rachel Cook, Gabrielle Meyers, Arpita Gandhi, Jessica T. Leonard, Brandon Hayes-Lattin, Laura F. Newell, Richard T Maziarz, Jennifer N. Saultz, Elie Traer, Theodore P Braun, Ronan T. Swords, Shannon K McWeeney, Jeffrey W Tyner
Journal: Blood
Blood (2023) 142 (Supplement 1): 978.
https://doi.org/10.1182/blood-2023-179527
Published: 2023
Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed
Journal: Blood
Blood (2023) 142 (Supplement 1): 4887.
https://doi.org/10.1182/blood-2023-182837
Published: 2023
Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Michael Scordo, Jessica R. Flynn, Sean M. Devlin, Mithat Gonen, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph E. Maakaron, Richard T. Maziarz, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood
Blood (2022) 140 (Supplement 1): 1588–1591.
https://doi.org/10.1182/blood-2022-164674
Published: 2022
Journal Articles

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Richard T. Maziarz, Steven M Devine, Louis P. Garrison, Irene Agodoa, Jack Badaracco, Matthew Gitlin, Miguel-Angel Perales
Journal: Blood
Blood (2022) 140 (Supplement 1): 10833–10834.
https://doi.org/10.1182/blood-2022-157439
Published: 2022
Journal Articles

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Arthur Nguyen, Joseph S Bubalo, Jennifer N. Saultz, Brandon Hayes-Lattin, Andy Chen, Rachel J. Cook, Arpita Gandhi, Jessica Leonard, Richard T. Maziarz, Yazan Migdady, Eneida R. Nemecek, Levanto Schachter
Journal: Blood
Blood (2022) 140 (Supplement 1): 12856–12858.
https://doi.org/10.1182/blood-2022-156011
Published: 2022
Journal Articles

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 10971–10973.
https://doi.org/10.1182/blood-2022-155886
Published: 2022
Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph E. Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul J. Shaughnessy, Armin Ghobadi, Michael R. Bishop, Ana Alfonso-Pierola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant Cohen, Richard T. Maziarz, Carlos Bachier
Journal: Blood
Blood (2022) 140 (Supplement 1): 10303–10306.
https://doi.org/10.1182/blood-2022-166432
Published: 2022
Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 366–368.
https://doi.org/10.1182/blood-2022-165556
Published: 2022
Journal Articles

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael Pratta, Lea Burke, John F. DiPersio, Richard T. Maziarz, Patricia Feldman, Teresa Brodeur, Cynthia Timmers, Olga Ivanova, April Barbour, Rodica Morariu-Zamfir, Matthew Frigault
Journal: Blood
Blood (2022) 140 (Supplement 1): 10350–10351.
https://doi.org/10.1182/blood-2022-169382
Published: 2022
Journal Articles

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Clinical Trials & Observations
Jordan Gauthier, Nicolas Gazeau, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A. Chow, Ajay K. Gopal, Alexandria Hodges Dwinal, Staci Williamson, Jessie Myers, Andy Chen, Sarah Nagle, Brandon Hayes-Lattin, Levanto Schachter, David G. Maloney, Cameron J. Turtle, Mohamed L. Sorror, Richard T. Maziarz
Journal: Blood
Blood (2022) 139 (26): 3722–3731.
https://doi.org/10.1182/blood.2021014497
Published: 2022
Includes: Supplemental data
Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquin Martinez-Lopez, Antonia MS Mueller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Chris Del Corral, Giovanna Andreola, Aisha Masood, Stephen J Schuster, Ulrich Jaeger, Peter Borchmann, Jason R. Westin
Journal: Blood
Blood (2021) 138 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2021-155068
Published: 2021
Journal Articles

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Kitsada Wudhikarn, Ana Alarcon Tomas, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Joseph P. McGuirk, Loretta Nastoupil, David L. Porter, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood
Blood (2021) 138 (Supplement 1): 2843.
https://doi.org/10.1182/blood-2021-150012
Published: 2021